Introduction: Chemokine receptors are important therapeutic targets for the treatment of
many human diseases. This study will provide an overview of approved chemokine receptor …

Douglas E Joshua, Christian Bryant, Caroline Dix, John Gibson, Joy Ho Multiple myeloma is
a malignancy of plasma cells originating from the bone marrow; it is a clonal plasma cell …

Multiple myeloma (MM) accounts for 10% of haematological malignancies. Overall survival
(OS) has improved in recent years due to increased use of autologous stem cell …

Despite therapeutic advances over the past decades, multiple myeloma (MM) remains a
largely incurable disease with poor prognosis in high-risk patients, and thus new treatment …

High-dose therapy (HDT) and autologous stem-cell transplantation (ASCT) has historically
been an essential part of multiple myeloma (MM) management since early studies …

Over the last few decades, hematopoietic stem cell transplantation (HSCT) has become an
established, life-saving, and a curative treatment option for many indications, including …

Background: Multiple myeloma (MM) is a malignant plasma cell disease. In recent years,
several systematic reviews, and meta-analyses have been published on treatment protocols …

Treatment of multiple myeloma (MM) has notably evolved with improved patient outcomes
over the past few years. Several new drugs have become available, and large national and …

Objectives Progress in multiple myeloma treatment allows patients to achieve deeper
responses, for which the assessment of minimal residual disease (MRD) is critical. Typically …

Introduction Myeloma, a blood cancer originating from plasma cells, is the most common
indication for autologous stem cell transplantation (SCT). Patients with myeloma undergoing …